Journal of Food and Drug Analysis (JFDA)
【Update Date:2022-03-24】unit:
A three-step stacking capillary electrophoresis of field-amplified sample injection, sweeping, and micellar collapse for determination of dabigatran and its active metabolite in human plasma
Cheng-Wei Cheng a, Wen-Han Feng b, Wei-Hua Tang c, Hwang-Shang Kou a, Chun-Chi Wang a,d,e,*, Shou-Mei Wu f,g,**
a School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC
b Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung
Medical University, Kaohsiung, Taiwan, ROC
c Department of Internal Medicine, Taipei Veterans General Hospital Yuli Branch, Hualian, Taiwan, ROC
d Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC
e Drug Development and Value Creation Research Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC
f Department of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC
g Taiwan Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan, ROC
A three-step stacking capillary electrophoresis (CE) composed of field-amplified sample injection, sweeping, and analyte focusing by micellar collapse (FASI-sweeping-AFMC) was developed to determine dabigatran (D) and its major active metabolite, dabigatran acyl-beta-d-glucuronide (DAG), in human plasma. After optimization and validation, this novel approach was further applied to monitor 5 real samples, and the 25.2 to 186.8 ng mL-1 D could be observed among those. Based on these results, the novel CE stacking strategy was successfully applied for the analysis of D and DAG in human plasma and could be served as a tool for clinical assays.
Keywords: Anticoagulant, Dabigatran, Dabigatran acyl-beta-d-glucuronide, FASI-sweeping-AFMC, Human plasma
https://doi.org/10.38212/2224-6614.3391